Novozymes (CPSE:NSIS B) - Cotización, noticias y análisis

Resumen de acción NSIS B

NSIS B fundamental analysis
Snowflake Score
Valuation	0/6
Future Growth	3/6
Past Performance	3/6
Financial Health	4/6
Dividends	3/6

Recompensas

Se prevé un crecimiento anual de los beneficios de 17.52%

Análisis de riesgos

Los accionistas han sido diluidos sustancialmente en el último año

Tiene un alto nivel de endeudamiento

Competidores de Novozymes A/S

Chr. Hansen Holding

CPSE:CHR

kr.72.3b

PPG Industries

NYSE:PPG

US$30.4b

DuPont de Nemours

NYSE:DD

US$30.3b

Asian Paints

NSEI:ASIANPAINT

₹2.8t

Historial de precios y rendimiento

Summary of all time highs, changes and price drops for Novozymes
Historical stock prices
Current Share Price	kr.383.60
52 Week High	kr.421.70
52 Week Low	kr.274.60
Beta	0.48
1 Month Change	-5.33%
3 Month Change	3.23%
1 Year Change	10.39%
3 Year Change	-14.22%
5 Year Change	20.78%
Change since IPO	1,083.95%

Noticias y actualizaciones recientes

Recent updates

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 27

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Sep 05

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

Sep 13

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Aug 29

Estimating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Jul 13

Here's Why Novozymes (CPH:NZYM B) Can Manage Its Debt Responsibly

Jun 13

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

May 29

Estimating The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Apr 12

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Mar 01

Here's What's Concerning About Novozymes' (CPH:NZYM B) Returns On Capital

Feb 14

Is Novozymes A/S (CPH:NZYM B) Worth kr.537 Based On Its Intrinsic Value?

Jan 01

We Think Novozymes (CPH:NZYM B) Can Stay On Top Of Its Debt

Nov 28

Many Would Be Envious Of Novozymes' (CPH:NZYM B) Excellent Returns On Capital

Nov 11

Is Novozymes A/S (CPH:NZYM B) Expensive For A Reason? A Look At Its Intrinsic Value

Sep 25

Rentabilidad de los accionistas

	NSIS B	DK Chemicals	Mercado DK
7D	-1.1%	-1.2%	0.3%
1Y	10.4%	0.2%	26.9%

Rentabilidad vs. Industria: NSIS B superó al sector Danish Chemicals , que obtuvo un rendimiento del -1.8% el año pasado.

Rentabilidad vs. Mercado: NSIS B obtuvo unos resultados inferiores a los del mercado Danish, que fue del 26.5% el año pasado.

Volatilidad de los precios

Is NSIS B's price volatile compared to industry and market?
NSIS B volatility
NSIS B Average Weekly Movement	3.1%
Chemicals Industry Average Movement	4.8%
Market Average Movement	4.6%
10% most volatile stocks in DK Market	9.6%
10% least volatile stocks in DK Market	2.9%

Precio estable de las acciones: NSIS B no ha tenido una volatilidad de precios significativa en los últimos 3 meses.

Volatilidad a lo largo del tiempo: La volatilidad semanal de NSIS B (3%) se ha mantenido estable durante el año pasado.

Acerca de la empresa

Fundada	Empleados	CEO	Página web
1925	6,577	Ester Baiget	www.novozymes.com

Novozymes A/S produce y vende enzimas industriales, microorganismos y probióticos en Dinamarca, el resto de Europa, Norteamérica, Asia-Pacífico, Oriente Medio, África, Latinoamérica y a escala internacional. La empresa ofrece soluciones proteínicas para la industria alimentaria y de bebidas. También ofrece servicios de higiene industrial, desatascadores de desagües, superficies duras, limpieza médica, fosas sépticas, lavado de vajillas y lavandería profesional.

Resumen de fundamentos de Novozymes A/S

¿Cómo se comparan los beneficios e ingresos de Novozymes con su capitalización de mercado?
Estadísticas fundamentales de NSIS B
Capitalización bursátil	kr.180.55b
Beneficios(TTM)	kr.3.02b
Ingresos (TTM)	kr.17.90b

58.9x

Ratio precio-beneficio (PE)

10.0x

Ratio precio-ventas (PS)

¿Está NSIS B sobrevalorada?

Ver valor justo y análisis de valoración

Beneficios e Ingresos

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de NSIS B
Ingresos	kr.17.90b
Coste de los ingresos	kr.8.18b
Beneficio bruto	kr.9.72b
Otros gastos	kr.6.70b
Beneficios	kr.3.02b

Últimos beneficios comunicados

Dec 31, 2023

Próxima fecha de beneficios

Aug 28, 2024

Beneficios por acción (BPA)	6.51
Margen bruto	54.32%
Margen de beneficio neto	16.89%
Ratio deuda/patrimonio	51.6%

¿Cómo se ha desempeñado NSIS B a largo plazo?

Ver rendimiento histórico y comparativa

Dividendos

1.6%

Rentabilidad actual por dividendo

88%

Ratio de pagos

¿Paga NSIS B dividendos fiables?

Ver historial de dividendos e índices de referencia de NSIS B

¿Cuándo hay que comprar NSIS B para recibir un próximo dividendo?
fechas de dividendos de Novozymes
Fecha ex dividendo	May 01 2024
Fecha de pago de dividendos	May 03 2024
Días hasta ex dividendo	1 day
Días hasta la fecha de pago de dividendos	1 day

¿Paga NSIS B dividendos fiables?

Ver historial de dividendos e índices de referencia de NSIS B

Resumen de acción NSIS B

Recompensas

Análisis de riesgos

Competidores de Novozymes A/S

CPSE:CHR

kr.72.3b

NYSE:PPG

US$30.4b

NYSE:DD

US$30.3b

NSEI:ASIANPAINT

₹2.8t

Historial de precios y rendimiento

Noticias y actualizaciones recientes

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Recent updates

Novozymes A/S Approves Dividend for the Last Four Months Ended December 31, 2023

Upcoming dividend of kr.2.00 per share

Novozymes A/S Proposes Dividend for the Last Four Months Ended December 31, 2023

Novonesis Provides Earnings Guidance for the Year 2024

Novonesis to Unveil Fit-for-Food Mood-Support Probiotic at Natural Product Expo West

Novozymes A/S Announces Board Appointments

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Consensus EPS estimates increase by 13%

Novozymes A/S to Report First Half, 2024 Results on Aug 28, 2024

Consensus EPS estimates increase by 14%

Full year 2023 earnings: Revenues in line with analyst expectations

New major risk - Shareholder dilution

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) completed the acquisition of Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S to Report Fiscal Year 2023 Final Results on Apr 08, 2024

Novozymes Launches Quara(R) Lowp for Renewable Diesel Feedstock Pre-T Treatment

Novozymes Launches ProSilience™ HU58

Third quarter 2023 earnings: Revenues exceed analyst expectations

Novozymes A/S Approves Interim Dividend, Payable on October 17, 2023

Novozymes A/S and Chr. Hansen Announce Executive Leadership Team and Organizational Structure

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

An Intrinsic Calculation For Novozymes A/S (CPH:NZYM B) Suggests It's 22% Undervalued

Now 21% undervalued after recent price drop

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Novozymes A/S Announces Change to the Executive Leadership Team

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Novozymes (CPH:NZYM B) Might Be Having Difficulty Using Its Capital Effectively

Does Novozymes (CPH:NZYM B) Have A Healthy Balance Sheet?

Is Now The Time To Put Novozymes (CPH:NZYM B) On Your Watchlist?

Upcoming dividend of kr.6.00 per share at 1.8% yield

Novozymes' (CPH:NZYM B) Profits Appear To Have Quality Issues

Independent Chairman recently bought kr.1.0m worth of stock

Calculating The Fair Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S Provides Earnings Guidance for the Year 2023

Full year 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Announces Jørgen Buhl Rasmussen Decides Not to Seek Re-Election as Member of its Board of Directors

Is Novozymes (CPH:NZYM B) Using Too Much Debt?

Investor sentiment deteriorated over the past week

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Novozymes A/S (CPSE:NZYM B) agreed to acquire Chr. Hansen Holding A/S (CPSE:CHR).

Returns On Capital At Novozymes (CPH:NZYM B) Paint A Concerning Picture

Less than half of directors are independent

Third quarter 2022 earnings: Revenues in line with analyst expectations

Novozymes A/S Provides Earnings Guidance for the Year 2022

Biotalys Nv and Novozymes A/S Announces Successful Evoca™ Feasibility Study

A Look At The Intrinsic Value Of Novozymes A/S (CPH:NZYM B)

Novozymes A/S to Report Q3, 2022 Results on Nov 03, 2022

Now 21% undervalued after recent price drop

Now 20% undervalued after recent price drop

These 4 Measures Indicate That Novozymes (CPH:NZYM B) Is Using Debt Reasonably Well

The Returns On Capital At Novozymes (CPH:NZYM B) Don't Inspire Confidence

Consensus EPS estimates increase by 11%

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations